<DOC>
	<DOCNO>NCT00614965</DOCNO>
	<brief_summary>This trial compare efficacy irinotecan/cisplatin pemetrexed/cisplatin second-line treatment patient stage IIIB/IV NSCLC</brief_summary>
	<brief_title>Irinotecan Plus Cisplatin v Pemetrexed Plus Cisplatin 2nd Line NSCLC Stage IIIB/IV</brief_title>
	<detailed_description>Non-platinum-based doublet include new drug use instead platinum-based regimen first line treatment patient advance NSCLC . Docetaxel pemetrexed proven effective second-line treatment patient NSCLC . In study conduct group combination irinotecan/cisplatin demonstrate high response rate cisplatin monotherapy patient progress first-line docetaxel/gemcitabine . Moreover , pemetrexed combine platinum ( ie , cisplatin , carboplatin , oxaliplatin ) NSCLC yield clinical activity similar platinum-based doublet . The efficacy different platinum-based combination patient pretreated non-platinum base first-line chemotherapy know .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Age 18 75 year Performance status ( WHO ) &lt; 2 Patients progress firstline docetaxel/gemcitabine treatment Adequate bone marrow ( absolute neutrophil count &gt; 1000/mm3 , platelet count &gt; 100000/mm3 , hemoglobin &gt; 9 gr/ mm3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal ) , renal ( Creatinine clearance &gt; 50mg/min ) cardiac ( LVEF &gt; 50 % ) function Presence measurable disease ( accord RESIST criterion ) Informed consent Psychiatric illness social situation would preclude study compliance ' Other concurrent uncontrolled illness . Other invasive malignancy within past 5 year except nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>second-line chemotherapy</keyword>
	<keyword>irinotecan</keyword>
	<keyword>pemetrexed</keyword>
</DOC>